What is the recommended treatment and follow‑up for a 76‑year‑old woman with mild interstitial lung disease characterized by parenchymal thickening/fibrosis?

Treatment for 76-Year-Old Female with Mild ILD/Fibrosis

For a 76-year-old woman with mild interstitial lung disease characterized by parenchymal thickening/fibrosis, the primary approach is close monitoring with pulmonary function tests and high-resolution CT chest rather than immediate pharmacologic treatment, unless there is evidence of progression or an underlying systemic autoimmune rheumatic disease requiring specific therapy.

Initial Diagnostic Clarification

Before determining treatment, you must establish whether this is:

• Idiopathic pulmonary fibrosis (IPF) - most common in elderly, accounts for ~33% of ILD cases 1
• Connective tissue disease-associated ILD (CTD-ILD) - accounts for 25% of cases 1
• Other ILD subtypes (hypersensitivity pneumonitis, etc.)

Screen for underlying systemic autoimmune rheumatic diseases (rheumatoid arthritis, systemic sclerosis, inflammatory myopathies, Sjögren disease, mixed connective tissue disease) as these fundamentally change management 2. Look specifically for:

• Joint symptoms, skin changes, Raynaud's phenomenon, muscle weakness
• Autoantibody testing: RF, anti-CCP, ANA with pattern, anti-Scl-70, myositis panel
• This is critical because CTD-ILD responds to immunomodulation while IPF does not

Monitoring Strategy for Mild Disease

For mild, stable disease without progression, adopt a surveillance approach:

• Pulmonary function tests every 6-12 months - specifically FVC and DLCO 2
• HRCT chest - frequency based on risk factors and stability 2
• Ambulatory desaturation testing during monitoring 2
• Avoid routine 6-minute walk distance, chest radiography, or bronchoscopy for monitoring 2

The key threshold: A 5% decline in FVC over 12 months indicates progression and approximately doubles mortality risk 1. This triggers treatment consideration.

Treatment Initiation Criteria

Start pharmacologic therapy if:

1. Progressive disease defined by worsening symptoms, ≥5% FVC decline, or radiological progression
2. Underlying CTD-ILD is identified - treat even if mild/stable
3. High-risk features suggesting likely progression

Treatment by Etiology

If IPF or Progressive Fibrosing ILD (Non-CTD):

First-line: Antifibrotic therapy with nintedanib or pirfenidone 1

• These slow annual FVC decline by 44-57% in IPF and progressive pulmonary fibrosis 1
• Both are appropriate first-line options
• Common pitfall: Nintedanib causes frequent GI side effects (diarrhea, nausea); pirfenidone causes photosensitivity and GI upset 3
• In elderly patients, start at lower doses and titrate based on tolerance 3

If CTD-ILD (SSc, RA, IIM, MCTD, SjD):

First-line: Mycophenolate 4

• Strongly recommended as initial therapy for CTD-ILD
• Monitor CBC, LFTs at baseline, 2 weeks, 4 weeks, 2 months, 3 months after starting, then every 3 months 4

Alternative first-line options based on specific CTD:

• Systemic sclerosis-ILD: Mycophenolate OR tocilizumab (studied in early SSc-ILD) 4, 5
• RA-ILD: Mycophenolate preferred; rituximab also effective 4
• IIM-ILD: Mycophenolate or rituximab 4

Avoid long-term glucocorticoids (>3-6 months) - strong recommendation against in SSc-ILD due to scleroderma renal crisis risk 4. May use short-term only for flares or as bridge therapy.

If Disease Progresses Despite First Treatment:

For CTD-ILD progression:

• Switch to or add: rituximab, cyclophosphamide, or nintedanib 4
• For RA-ILD specifically: Consider adding pirfenidone 4
• For SSc-ILD, MCTD-ILD, RA-ILD: Tocilizumab is an option 4

Essential Supportive Care (All Patients)

Implement regardless of pharmacologic treatment:

• Pulmonary rehabilitation - improves 6-minute walk distance and quality of life 1
• Supplemental oxygen if desaturation <88% on 6-minute walk test 1
• Gastroesophageal reflux management with proton pump inhibitors 4
• PJP prophylaxis (trimethoprim-sulfamethoxazole) if on immunosuppression 4
• Smoking cessation if applicable 4
• Early palliative care consultation for symptom management (dyspnea, cough) 4, 6

Age-Specific Considerations for 76-Year-Old

Critical factors in elderly ILD management 3:

• Assess frailty vs. robustness - influences treatment intensity
• Screen for comorbidities: pulmonary hypertension (present in up to 85% of advanced fibrotic ILD), lung cancer risk, cardiovascular disease 1, 7
• Drug-drug interactions: Elderly patients often on multiple medications; antifibrotics and immunosuppressants have significant interaction profiles 3
• Lower starting doses with gradual titration improves tolerability 3
• Lung transplant evaluation if appropriate - median post-transplant survival 5.2-6.7 years vs. <2 years without transplant in advanced disease 1, though age 76 may limit candidacy

Common Pitfalls to Avoid

1. Starting treatment without establishing progression - mild stable disease may not require immediate pharmacotherapy
2. Using glucocorticoids long-term - particularly dangerous in SSc-ILD 4
3. Missing underlying CTD - fundamentally changes treatment from antifibrotics to immunomodulation
4. Inadequate monitoring frequency - must detect 5% FVC decline threshold 1
5. Neglecting supportive care - pulmonary rehabilitation and oxygen improve quality of life even when disease-modifying therapy is limited 1